PRAX stock forecast, quote, news & analysis
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company... Show more
Why Praxis Precision Medicines (PRAX) Stock Is Up +21% in the Last 30 Days
Key Takeaways
- PRAX shares surged approximately 21% over the last 30 days, rebounding from a steep early-June sell-off triggered by a failed Phase 2/3 epilepsy trial.
- Over the full quarter, the stock is down roughly 6%, reflecting extreme intra-quarter volatility rather than a sustained downtrend.
- Multiple Wall Street firms — including Goldman Sachs, RBC Capital, Needham, and Piper Sandler — initiated or reiterated bullish ratings during the period, fueling the recovery.
- The FDA accepted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A/8A-DEE), with PDUFA dates set for January 2027 and September 2026 respectively, reinforcing the company's transition toward commercialization.
- Elsunersen received Breakthrough Therapy Designation after demonstrating a 77% placebo-adjusted reduction in monthly seizures in the EMBRAVE Part A study.
- The company's cash position of approximately $787 million is expected to fund operations into 2028, reducing near-term dilution risk.
Praxis Precision Medicines (PRAX) Company Overview and Market Position
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. Headquartered in Boston, Massachusetts, Praxis leverages two proprietary platforms — Cerebrum (small molecule) and Solidus (antisense oligonucleotide) — to target genetic epilepsies, movement disorders, and other neurological conditions. The company's late-stage pipeline includes four key assets: ulixacaltamide for essential tremor, relutrigine for developmental and epileptic encephalopathies (DEEs), vormatrigine for focal onset seizures, and elsunersen for SCN2A-DEE. With a market capitalization exceeding $9 billion and zero debt, Praxis is closely watched by biotech investors as it approaches its first potential FDA approvals and commercial launches.
Praxis Precision Medicines (PRAX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, PRAX shares climbed from a closing price of $264.54 on June 15, 2026, to an intraday level of approximately $320.81 on July 15, 2026 — a gain of approximately 21.3%. The rally represents a sharp recovery from the stock's early-June trough, when shares plunged as low as $238.77 intraday on June 10 following disappointing clinical trial results. The rebound has been broad-based, supported by improving sentiment across the biotechnology sector and a wave of positive analyst actions.
Zooming out to the trailing quarter, the stock is down roughly 6%, with a closing price of $339.93 on April 15, 2026, compared to the most recent level. The quarterly performance masks significant intra-period swings: shares traded as high as $366.52 in late May before the early-June sell-off erased those gains. The stock's elevated beta of approximately 2.76 underscores its sensitivity to pipeline news and regulatory developments.
What Drove PRAX Stock Price in the Last 30 Days
The 30-day advance was primarily a recovery rally following an early-June sell-off tied to a failed Phase 2/3 epilepsy trial. Once the initial negative reaction subsided, investor focus shifted back to Praxis's broader pipeline and regulatory progress.
Several catalysts fueled the rebound. On June 29, Needham raised its price target on Praxis to $575 while reiterating a Buy rating. In mid-July, Goldman Sachs initiated coverage with a Buy rating and a $447 price target, projecting that ulixacaltamide would likely receive FDA approval by its January 2027 PDUFA date and estimating unadjusted U.S. peak sales of approximately $5 billion by 2035. Piper Sandler also reiterated its Overweight rating and $1,200 price target, citing a 95% probability of success for ulixacaltamide's regulatory approval. RBC Capital initiated coverage with a Buy rating and a $449 target on June 17.
On the regulatory front, the FDA granted Breakthrough Therapy Designation to elsunersen for SCN2A-DEE, a milestone that validated the drug's clinical profile and accelerated its development timeline. Meanwhile, the completion of recruitment for the relutrigine EMERALD study in broad DEEs, with topline results expected in Q4 2026, sustained optimism around the company's epilepsy franchise. The relutrigine NDA review was extended by three months to December 27, 2026, following the submission of additional sensitivity analyses — a delay that was largely absorbed without triggering a new sell-off.
Short interest data also played a role. As of June 30, 2026, short interest stood at approximately 3.99 million shares (roughly 5.2 days to cover), up from 3.57 million in mid-June — indicating that some of the upward move may have been amplified by short-squeeze dynamics amid the improving news flow.
What Drove PRAX Stock Performance Over the Last Quarter
The broader quarterly trend reflects Praxis's transition from a development-stage biotech to a pre-commercial organization. In early May, the company reported Q1 2026 financial results and confirmed FDA acceptance of NDAs for both ulixacaltamide and relutrigine — a watershed moment that set the stage for two potential U.S. product launches within eight months. The company also announced that the EMBRAVE Part A study of elsunersen demonstrated a 77% placebo-adjusted reduction in monthly seizures, with evidence of disease-modifying improvements in pediatric patients.
However, the quarter's net negative return was driven almost entirely by the early-June clinical setback, which overshadowed positive developments that had propelled shares toward their 52-week high in late May. The failed Phase 2/3 epilepsy readout — combined with the subsequent relutrigine FDA review extension — reminded investors of the binary risk inherent in biotech pipelines, even for companies with multiple late-stage assets. Nevertheless, Praxis ended the quarter with approximately $787 million in cash and negligible debt, giving it ample runway to fund operations into 2028 without needing to access capital markets under adverse conditions.
Trending AI Robots
For investors seeking a data-driven approach to navigating volatility in stocks like Praxis Precision Medicines, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron hosts hundreds of AI-powered trading bots that actively trade thousands of tickers across multiple strategies and timeframes, but only the most relevant and consistently strong performers are featured in this section. These bots vary in strategy — ranging from short-term momentum plays to longer-duration trend-following models — and include detailed performance metrics to help users evaluate their track records. Exploring the Trending AI Robots page can provide traders with an additional analytical lens when assessing stocks with elevated volatility and binary event risk.
PRAX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several high-impact catalysts could shape Praxis's stock trajectory. The relutrigine PDUFA date of December 27, 2026, represents the nearest major regulatory decision and the company's first potential product approval. Topline results from the EMERALD study in broad DEEs, expected in Q4 2026, could significantly expand relutrigine's addressable market beyond the initial SCN2A/SCN8A indication.
The ulixacaltamide PDUFA date of January 29, 2027, remains the centerpiece of Praxis's commercial thesis, with the company projecting over $10 billion in peak sales potential. Investors should also monitor topline data from the POWER1 study of vormatrigine in focal onset seizures, anticipated in the second half of 2026. On the macroeconomic side, sector-wide sentiment toward pre-revenue biotech companies, interest rate expectations, and broader risk appetite will continue to influence PRAX's valuation. Competitive developments in the CNS space, manufacturing readiness for commercial launches, and potential partnership or M&A activity represent additional variables worth tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PRAX in upward trend: price rose above 50-day moving average on July 21, 2026
PRAX moved above its 50-day moving average on July 21, 2026 date and that indicates a change from a downward trend to an upward trend. In of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where PRAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on PRAX as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for PRAX crossed bullishly above the 50-day moving average on July 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PRAX advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PRAX moved out of overbought territory on June 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for PRAX turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PRAX broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PRAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.431) is normal, around the industry mean (19.191). P/E Ratio (0.000) is within average values for comparable stocks, (38.162). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.511). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (394.782).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology